TiGenix, the coordinator of the international Regener-AR consortium, has received a grant of nearly $3.8 million from the European Seventh Framework Programme, or FP7. The money will be used for the research and development of Cx611, TiGenix's allogeneic adult stem cell treatment for rheumatoid arthritis. Including the TiGenix grant, the consortium will get nearly $7.7 million from FP7.

Related Summaries